APA to Include Biomarkers in Next DSM Edition Despite Limited Clinical Validation

The American Psychiatric Association announced it will be including biomarkers for mental conditions in the next edition of the Diagnostic and Statistical Manual of Mental Disorders, potentially shifting how mental illnesses are diagnosed and treated. Mental health conditions traditionally have been diagnosed based on symptoms rather than measurable biological indicators.

The APA said in a paper published Jan. 27 in The American Journal of Psychiatry that biomarkers — such as blood-based inflammatory markers, genetic profiles or brain activity patterns — could help clinicians make more precise diagnoses and guide treatment selection, though not validated for routine use. Despite major advances in our understanding of the biology of mental health disorders, there's no blood test or brain scan that will confirm if you have depression, anxiety, PTSD, or any other psychiatric illness.

Research into psychiatric biomarkers has spanned decades with limited clinical adoption. One large early-2000s study found about 30% of patients with depression saw symptoms resolve with their first antidepressant, highlighting variability in treatment response.

Some findings point toward potential clinical use. About 25% of patients with depression have elevated levels of C-reactive protein, an inflammatory marker that may indicate better response to certain non-SSRI treatments. However, the APA said such markers are not yet validated for routine use.

Adoption of biomarker-driven psychiatry could also affect costs and coverage. Some studies suggest testing may reduce long-term spending by removing treatment selection, though much of that research has come from outside the U.S. Limited insurance coverage could slow adoption.

The APA called for more coordinated, well-funded research to validate biomarkers, noting recent federal funding cuts have created uncertainty.